{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T16:28:30Z","timestamp":1746289710133},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologe"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s00120-015-0025-x","type":"journal-article","created":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T17:14:03Z","timestamp":1454346843000},"page":"269-281","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Aktive \u00dcberwachung beim Niedrig-Risiko-Prostatakarzinom"],"prefix":"10.1007","volume":"55","author":[{"given":"Annika","family":"Herlemann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian G.","family":"Stief","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,1]]},"reference":[{"key":"25_CR1","volume-title":"Prostatakrebs","author":"Robert-Koch-Institut","year":"2010","unstructured":"Robert-Koch-Institut (2010) Prostatakrebs. http:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Publikationen\/Krebs_in_Deutschland\/kid_2015\/kid_2015_c61_prostata.pdf?__blob=publicationFile . Zugegriffen: 17.\u00a0Januar 2016"},{"issue":"2","key":"25_CR2","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0022-5347(05)67373-9","volume":"164","author":"RF Hoedemaeker","year":"2000","unstructured":"Hoedemaeker RF et al (2000) Histopathological prostate cancer characteristics at radical prostatectomy after population based screening. J Urol 164(2):411\u2013415","journal-title":"J Urol"},{"issue":"1","key":"25_CR3","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.eururo.2013.09.046","volume":"65","author":"A Heidenreich","year":"2014","unstructured":"Heidenreich A et al (2014) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65(1):124\u2013137","journal-title":"Eur Urol"},{"issue":"12","key":"25_CR4","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1002\/ijc.29408","volume":"137","author":"JL Jahn","year":"2015","unstructured":"Jahn JL, Giovannucci EL, Stampfer MJ (2015) The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate-specific Antigen-era. Int J Cancer 137(12):2795\u20132802","journal-title":"Int J Cancer"},{"issue":"8","key":"25_CR5","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1002\/cncr.23373","volume":"112","author":"MA Dall\u2019Era","year":"2008","unstructured":"Dall\u2019Era MA et al (2008) Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 112(8):1650\u20131659","journal-title":"Cancer"},{"issue":"3","key":"25_CR6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00120-008-1638-0","volume":"47","author":"M Graefen","year":"2008","unstructured":"Graefen M et al (2008) Active surveillance for prostate cancer. Urologe A 47(3):261\u2013269","journal-title":"Urologe A"},{"issue":"7","key":"25_CR7","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00120-014-3535-z","volume":"53","author":"K Lellig","year":"2014","unstructured":"Lellig K et al (2014) Active surveillance of low risk prostate cancer. Urologe A 53(7):1031\u20131039","journal-title":"Urologe A"},{"issue":"19","key":"25_CR8","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1055\/s-0041-102939","volume":"140","author":"A Spek","year":"2015","unstructured":"Spek A et al (2015) PSA screening. Dtsch Med Wochenschr 140(19):1435\u20131437","journal-title":"Dtsch Med Wochenschr"},{"issue":"1","key":"25_CR9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0022-5347(01)67248-3","volume":"154","author":"AV D\u2019Amico","year":"1995","unstructured":"D\u2019Amico AV et al (1995) A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 154(1):131\u2013138","journal-title":"J Urol"},{"issue":"3","key":"25_CR10","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.juro.2011.02.2695","volume":"186","author":"JI Epstein","year":"2011","unstructured":"Epstein JI (2011) Prognostic significance of tumor volume in radical prostatectomy and needle biopsy specimens. J Urol 186(3):790\u2013797","journal-title":"J Urol"},{"key":"25_CR11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3410\/M4-16","volume":"4","author":"L Klotz","year":"2012","unstructured":"Klotz L (2012) Active surveillance for low-risk prostate cancer. F1000 Med Rep 4:16","journal-title":"F1000 Med Rep"},{"issue":"3","key":"25_CR12","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1464-410X.2010.09499.x","volume":"106","author":"K Trpkov","year":"2010","unstructured":"Trpkov K et al (2010) \u201cInsignificant\u201d prostate cancer on prostatectomy and cystoprostatectomy: variation on a theme \u201clow-volume\/low-grad\u201d prostate cancer? Br J Urol Int 106(3):304\u2013315","journal-title":"Br J Urol Int"},{"issue":"3 Suppl","key":"25_CR13","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/1097-0142(19930201)71:3+<933::AID-CNCR2820711408>3.0.CO;2-L","volume":"71","author":"TA Stamey","year":"1993","unstructured":"Stamey TA et al (1993) Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 71(3 Suppl):933\u2013938","journal-title":"Cancer"},{"issue":"5","key":"25_CR14","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1001\/jama.1994.03510290050036","volume":"271","author":"JI Epstein","year":"1994","unstructured":"Epstein JI et al (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271(5):368\u2013374","journal-title":"JAMA"},{"issue":"6 Pt 2","key":"25_CR15","first-page":"2407","volume":"160","author":"JI Epstein","year":"1998","unstructured":"Epstein JI et al (1998) Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free\/total prostate specific antigen levels and needle biopsy findings. J Urol 160(6 Pt 2):2407\u20132411","journal-title":"J Urol"},{"issue":"3","key":"25_CR16","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1464-410X.2006.06660.x","volume":"99","author":"MH Winkler","year":"2007","unstructured":"Winkler MH et al (2007) Characteristics of incidental prostatic adenocarcinoma in contemporary radical cystoprostatectomy specimens. Br J Urol Int 99(3):554\u2013558","journal-title":"Br J Urol Int"},{"issue":"1","key":"25_CR17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.juro.2010.08.082","volume":"185","author":"T Wolters","year":"2011","unstructured":"Wolters T et al (2011) A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol 185(1):121\u2013125","journal-title":"J Urol"},{"issue":"5","key":"25_CR18","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646\u2013674","journal-title":"Cell"},{"issue":"1","key":"25_CR19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57\u201370","journal-title":"Cell"},{"issue":"11","key":"25_CR20","doi-asserted-by":"crossref","first-page":"e509","DOI":"10.1016\/S1470-2045(12)70388-1","volume":"13","author":"HU Ahmed","year":"2012","unstructured":"Ahmed HU et al (2012) Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy? Lancet Oncol 13(11):e509\u2013e517","journal-title":"Lancet Oncol"},{"issue":"11","key":"25_CR21","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1002\/cncr.20243","volume":"100","author":"R Arora","year":"2004","unstructured":"Arora R et al (2004) Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer 100(11):2362\u20132366","journal-title":"Cancer"},{"issue":"2","key":"25_CR22","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.eururo.2012.03.050","volume":"63","author":"J Lindberg","year":"2013","unstructured":"Lindberg J et al (2013) Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. Eur Urol 63(2):347\u2013353","journal-title":"Eur Urol"},{"issue":"11","key":"25_CR23","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1172\/JCI70354","volume":"123","author":"MC Haffner","year":"2013","unstructured":"Haffner MC et al (2013) Tracking the clonal origin of lethal prostate cancer. J Clin Invest 123(11):4918\u20134922","journal-title":"J Clin Invest"},{"issue":"5","key":"25_CR24","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nm.1944","volume":"15","author":"W Liu","year":"2009","unstructured":"Liu W et al (2009) Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 15(5):559\u2013565","journal-title":"Nat Med"},{"issue":"6","key":"25_CR25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/gcc.21944","volume":"51","author":"LK Boyd","year":"2012","unstructured":"Boyd LK et al (2012) High-resolution genome-wide copy-number analysis suggests a monoclonal origin of multifocal prostate cancer. Genes Chromosomes Cancer 51(6):579\u2013589","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"25_CR26","first-page":"1286","volume":"191","author":"SS Taneja","year":"2014","unstructured":"Taneja SS (2014) Re: tracking the clonal origin of lethal prostate cancer. J Urol 191(5):1286\u20131289","journal-title":"J Urol"},{"issue":"4","key":"25_CR27","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/ng.3221","volume":"47","author":"CS Cooper","year":"2015","unstructured":"Cooper CS et al (2015) Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet 47(4):367\u2013372","journal-title":"Nat Genet"},{"key":"25_CR28","volume-title":"Interdisziplin\u00e4re Leitlinie der Qualit\u00e4t S3 zur Fr\u00fcherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Kurzversion 3.1, 2014 AWMF Registernummer: 043\/022OL","author":"Krebsgesellschaft","year":"2015","unstructured":"Krebsgesellschaft, Deutsche Krebshilfe, AWMF Interdisziplin\u00e4re Leitlinie der Qualit\u00e4t S3 zur Fr\u00fcherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Kurzversion 3.1, 2. Aktualisierung, Oktober 2014 AWMF Registernummer: 043\/022OL. http:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/043-022OLk_S3_Prostatakarzinom_2014-12.pdf . Zugegriffen: 12. November 2015"},{"issue":"2","key":"25_CR29","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.urolonc.2014.07.007","volume":"33","author":"G Ploussard","year":"2015","unstructured":"Ploussard G et al (2015) Can we expand active surveillance criteria to include biopsy Gleason 3+4 prostate cancer? A multi-institutional study of 2,323 patients. Urol Oncol 33(2):e1\u2013e9","journal-title":"Urol Oncol"},{"issue":"1","key":"25_CR30","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/bjc.2013.268","volume":"109","author":"M Camargo Cancela de","year":"2013","unstructured":"de Camargo Cancela M, Comber H, Sharp L (2013) Age remains the major predictor of curative treatment non-receipt for localised prostate cancer: a population-based study. Br J Cancer 109(1):272\u2013279","journal-title":"Br J Cancer"},{"issue":"2","key":"25_CR31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2010.30.2075","volume":"29","author":"SK Bechis","year":"2011","unstructured":"Bechis SK, Carroll PR, Cooperberg MR (2011) Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol 29(2):235\u2013241","journal-title":"J Clin Oncol"},{"issue":"2","key":"25_CR32","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/pcan.2015.1","volume":"18","author":"LM Wong","year":"2015","unstructured":"Wong LM et al (2015) Evaluation of models predicting insignificant prostate cancer to select men for active surveillance of prostate cancer. Prostate Cancer Prostatic Dis 18(2):137\u2013143","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"25_CR33","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/cncr.23610","volume":"113","author":"FK Chun","year":"2008","unstructured":"Chun FK et al (2008) Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men. Cancer 113(4):701\u2013709","journal-title":"Cancer"},{"issue":"6b","key":"25_CR34","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1111\/bju.12554","volume":"114","author":"SY Wang","year":"2014","unstructured":"Wang SY et al (2014) Limited ability of existing nomograms to predict outcomes in men undergoing active surveillance for prostate cancer. Br J Urol Int 114(6b):E18\u2013E24","journal-title":"Br J Urol Int"},{"issue":"7","key":"25_CR35","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00345-015-1510-y","volume":"33","author":"A Karl","year":"2015","unstructured":"Karl A et al (2015) The natural course of pT2 prostate cancer with positive surgical margin: predicting biochemical recurrence. World J Urol 33(7):973\u2013979","journal-title":"World J Urol"},{"issue":"2","key":"25_CR36","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.juro.2015.02.015","volume":"194","author":"KT Dinh","year":"2015","unstructured":"Dinh KT et al (2015) Incidence and predictors of upgrading and up staging among 10,000 contemporary patients with low risk prostate cancer. J Urol 194(2):343\u2013349","journal-title":"J Urol"},{"issue":"7","key":"25_CR37","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00345-015-1604-6","volume":"33","author":"E Lellig","year":"2015","unstructured":"Lellig E et al (2015) Final pathohistology after radical prostatectomy in patients eligible for active surveillance (AS). World J Urol 33(7):917\u2013922","journal-title":"World J Urol"},{"issue":"2","key":"25_CR38","doi-asserted-by":"crossref","first-page":"e0115537","DOI":"10.1371\/journal.pone.0115537","volume":"10","author":"I Heidegger","year":"2015","unstructured":"Heidegger I et al (2015) High risk of under-grading and -staging in prostate cancer patients eligible for active surveillance. PloS One 10(2):e0115537","journal-title":"PloS One"},{"issue":"3 Pt 1","key":"25_CR39","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.juro.2007.05.016","volume":"178","author":"CR Griffin","year":"2007","unstructured":"Griffin CR et al (2007) Pathological features after radical prostatectomy in potential candidates for active monitoring. J Urol 178(3 Pt 1):860\u2013863 (discussion 863)","journal-title":"J Urol"},{"issue":"5","key":"25_CR40","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.juro.2007.07.049","volume":"178","author":"ON Gofrit","year":"2007","unstructured":"Gofrit ON et al (2007) Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer. J Urol 178(5):1925\u20131928","journal-title":"J Urol"},{"key":"25_CR41","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2288-13-19","volume":"13","author":"E Rapiti","year":"2013","unstructured":"Rapiti E et al (2013) Importance and determinants of Gleason score undergrading on biopsy sample of prostate cancer in a population-based study. Bio Med Central Urol 13:19","journal-title":"Bio Med Central Urol"},{"key":"25_CR42","first-page":"\u25a0","volume":"\u25a0","author":"JW Davis","year":"2015","unstructured":"Davis JW et al (2015) Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. Br J Urol Int. doi:10.1111\/bju.13193","journal-title":"Br J Urol Int"},{"issue":"3","key":"25_CR43","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1464-410X.2004.04926.x","volume":"94","author":"R Choo","year":"2004","unstructured":"Choo R et al (2004) Wide variation of prostate-specific antigen doubling time of untreated, clinically localized, low-to-intermediate grade, prostate carcinoma. Br J Urol Int 94(3):295\u2013298","journal-title":"Br J Urol Int"},{"issue":"3","key":"25_CR44","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1464-410X.2006.05958.x","volume":"97","author":"SJ Teahan","year":"2006","unstructured":"Teahan SJ, Klotz LH (2006) Current role of prostate-specific antigen kinetics in managing patients with prostate cancer. Br J Urol Int 97(3):451\u2013455","journal-title":"Br J Urol Int"},{"issue":"2","key":"25_CR45","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/(SICI)1097-0142(19980115)82:2<349::AID-CNCR15>3.0.CO;2-Z","volume":"82","author":"DB McLaren","year":"1998","unstructured":"McLaren DB et al (1998) Watchful waiting or watchful progression?: Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer 82(2):342\u2013348","journal-title":"Cancer"},{"issue":"17","key":"25_CR46","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1200\/JCO.2009.25.7311","volume":"28","author":"AE Ross","year":"2010","unstructured":"Ross AE et al (2010) Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 28(17):2810\u20132816","journal-title":"J Clin Oncol"},{"issue":"5","key":"25_CR47","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.juro.2010.12.042","volume":"185","author":"JM Whitson","year":"2011","unstructured":"Whitson JM et al (2011) The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol 185(5):1656\u20131660","journal-title":"J Urol"},{"issue":"3","key":"25_CR48","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1464-410X.2012.11295.x","volume":"111","author":"V Iremashvili","year":"2013","unstructured":"Iremashvili V et al (2013) Comprehensive analysis of post-diagnostic prostate-specific antigen kinetics as predictor of a prostate cancer progression in active surveillance patients. Br J Urol Int 111(3):396\u2013403","journal-title":"Br J Urol Int"},{"issue":"3","key":"25_CR49","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","volume":"33","author":"L Klotz","year":"2015","unstructured":"Klotz L et al (2015) Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 33(3):272\u2013277","journal-title":"J Clin Oncol"},{"issue":"30","key":"25_CR50","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1200\/JCO.2015.62.5764","volume":"33","author":"JJ Tosoian","year":"2015","unstructured":"Tosoian JJ et al (2015) Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. J Clin Oncol 33(30):3379\u20133385","journal-title":"J Clin Oncol"},{"issue":"4","key":"25_CR51","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/S0022-5347(05)00646-4","volume":"175","author":"SJ Freedland","year":"2006","unstructured":"Freedland SJ et al (2006) Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer. J Urol 175(4):1298\u20131302 (discussion 1302\u20131303)","journal-title":"J Urol"},{"issue":"6","key":"25_CR52","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/j.juro.2011.02.009","volume":"185","author":"D O\u2019Brien","year":"2011","unstructured":"O\u2019Brien D et al (2011) Delay of surgery in men with low risk prostate cancer. J Urol 185(6):2143\u20132147","journal-title":"J Urol"},{"issue":"6","key":"25_CR53","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/j.juro.2011.07.117","volume":"186","author":"L Klotz","year":"2011","unstructured":"Klotz L (2011) Re: Delay of surgery in men with low risk prostate cancer: D O\u2019Brien, S Loeb, G F Carvalhal, B B McGuire, D Kan, M D Hofer, J T Casey, B T Helf and W J Catalona. J Urol 2011; 185: 2143\u20132147. J Urol 186(6):2505 (author reply 2506)","journal-title":"J Urol"},{"issue":"3","key":"25_CR54","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.eururo.2011.06.013","volume":"60","author":"RC Bergh van den","year":"2011","unstructured":"van den Bergh RC (2011) Words of wisdom: Re: Delay of surgery in men with low-risk prostate cancer. Eur Urol 60(3):597\u2013598","journal-title":"Eur Urol"},{"issue":"10","key":"25_CR55","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/pros.22992","volume":"75","author":"WT Berg","year":"2015","unstructured":"Berg WT et al (2015) Delay from biopsy to radical prostatectomy influences the rate of adverse pathologic outcomes. Prostate 75(10):1085\u20131091","journal-title":"Prostate"},{"issue":"4","key":"25_CR56","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.juro.2010.06.008","volume":"184","author":"B Holmstrom","year":"2010","unstructured":"Holmstrom B et al (2010) Outcome of primary versus deferred radical prostatectomy in the national prostate cancer register of sweden follow-up study. J Urol 184(4):1322\u20131327","journal-title":"J Urol"},{"issue":"30","key":"25_CR57","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1200\/JCO.2008.21.2613","volume":"27","author":"WV Shappley 3rd","year":"2009","unstructured":"Shappley WV 3rd et al (2009) Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol 27(30):4980\u20134985","journal-title":"J Clin Oncol"},{"issue":"5","key":"25_CR58","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/jnci\/djj072","volume":"98","author":"C Warlick","year":"2006","unstructured":"Warlick C et al (2006) Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 98(5):355\u2013357","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"25_CR59","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/cncr.24882","volume":"116","author":"RC Bergh van den","year":"2010","unstructured":"van den Bergh RC et al (2010) Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes? Cancer 116(5):1281\u20131290","journal-title":"Cancer"},{"key":"25_CR60","volume-title":"NICE clinical guideline 175. Prostate cancer: diagnosis and treatment","author":"National Institute for Health and Care Excellence (NICE)","year":"2014","unstructured":"National Institute for Health and Care Excellence (NICE) (2014) NICE clinical guideline 175. Prostate cancer: diagnosis and treatment. http:\/\/www.nice.org.uk\/guidance\/cg175\/chapter\/1-recommendations#localised-and-locally-advanced-prostate-cancer-2. Zugegriffen: 24 November 2015"},{"issue":"6","key":"25_CR61","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.eururo.2015.01.013","volume":"68","author":"JJ Futterer","year":"2015","unstructured":"Futterer JJ et al (2015) Can clinically significant prostate cancer be detected with Multiparametric magnetic resonance imaging? A systematic review of the literature. Eur Urol 68(6):1045\u20131053","journal-title":"Eur Urol"},{"key":"25_CR62","author":"M Rooij de","year":"2015","unstructured":"de Rooij M et al (2015) Accuracy of magnetic resonance imaging for local staging of prostate cancer: a diagnostic meta-analysis. Eur Urol. doi:10.3410\/f.725679060.793512189","journal-title":"Eur Urol"},{"issue":"7","key":"25_CR63","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00345-014-1448-5","volume":"33","author":"A Billing","year":"2015","unstructured":"Billing A et al (2015) Preoperative mp-MRI of the prostate provides little information about staging of prostate carcinoma in daily clinical practice. World J Urol 33(7):923\u2013928","journal-title":"World J Urol"},{"issue":"8","key":"25_CR64","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1055\/s-0033-1356186","volume":"186","author":"J Otto","year":"2014","unstructured":"Otto J et al (2014) Value of endorectal magnetic resonance imaging at 3 T for the local staging of prostate cancer. Rofo 186(8):795\u2013802","journal-title":"Rofo"},{"issue":"3","key":"25_CR65","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ejrad.2010.12.076","volume":"81","author":"O Ruprecht","year":"2012","unstructured":"Ruprecht O et al (2012) MRI of the prostate: interobserver agreement compared with histopathologic outcome after radical prostatectomy. Eur J Radiol 81(3):456\u2013460","journal-title":"Eur J Radiol"},{"key":"25_CR66","author":"KJ Tay","year":"2015","unstructured":"Tay KJ et al (2015) Defining the incremental utility of prostate multiparametric magnetic resonance imaging at standard and specialized read in predicting extracapsular extension of prostate cancer. Eur Urol. doi:10.1016\/j.eururo.2015.10.041","journal-title":"Eur Urol"},{"issue":"1","key":"25_CR67","first-page":"3429","volume":"14","author":"KC Latchamsetty","year":"2007","unstructured":"Latchamsetty KC et al (2007) Experience improves staging accuracy of endorectal magnetic resonance imaging in prostate cancer: what is the learning curve? Can J Urol 14(1):3429\u20133434","journal-title":"Can J Urol"},{"issue":"3","key":"25_CR68","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/MOU.0b013e32835eff24","volume":"23","author":"MW Kazer","year":"2013","unstructured":"Kazer MW et al (2013) Psychosocial aspects of active surveillance. Curr Opin Urol 23(3):273\u2013277","journal-title":"Curr Opin Urol"},{"issue":"3","key":"25_CR69","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.urology.2012.04.053","volume":"80","author":"D Seiler","year":"2012","unstructured":"Seiler D et al (2012) Protocol-based active surveillance for low-risk prostate cancer: anxiety levels in both men and their partners. Urology 80(3):564\u2013569","journal-title":"Urology"},{"issue":"3","key":"25_CR70","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/cncr.21198","volume":"104","author":"W Dale","year":"2005","unstructured":"Dale W et al (2005) The role of anxiety in prostate carcinoma \u2013 a structured review of the literature. Cancer 104(3):467\u2013478","journal-title":"Cancer"},{"issue":"1","key":"25_CR71","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.eururo.2013.01.023","volume":"64","author":"L Klotz","year":"2013","unstructured":"Klotz L (2013) Active surveillance, quality of life, and cancer-related anxiety. Eur Urol 64(1):37\u201339","journal-title":"Eur Urol"},{"issue":"2","key":"25_CR72","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.eururo.2012.02.002","volume":"62","author":"M Bul","year":"2012","unstructured":"Bul M et al (2012) Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study. Eur Urol 62(2):195\u2013200","journal-title":"Eur Urol"},{"issue":"11","key":"25_CR73","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1111\/j.1464-410X.2011.10200.x","volume":"108","author":"BJ Davison","year":"2011","unstructured":"Davison BJ, Goldenberg SL (2011) Patient acceptance of active surveillance as a treatment option for low-risk prostate cancer. Br J Urol Int 108(11):1787\u20131793","journal-title":"Br J Urol Int"},{"issue":"11","key":"25_CR74","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1111\/j.1464-410X.2011.10677.x","volume":"109","author":"H Vasarainen","year":"2012","unstructured":"Vasarainen H et al (2012) Prostate cancer active surveillance and health-related quality of life: results of the Finnish arm of the prospective trial. Br J Urol Int 109(11):1614\u20131619","journal-title":"Br J Urol Int"},{"issue":"18","key":"25_CR75","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa1011967","volume":"364","author":"A Bill-Axelson","year":"2011","unstructured":"Bill-Axelson A et al (2011) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364(18):1708\u20131717","journal-title":"N Engl J Med"},{"issue":"11","key":"25_CR76","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa021483","volume":"347","author":"G Steineck","year":"2002","unstructured":"Steineck G et al (2002) Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 347(11):790\u2013796","journal-title":"N Engl J Med"},{"issue":"3","key":"25_CR77","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1464-410X.2007.07009.x","volume":"100","author":"KL Burnet","year":"2007","unstructured":"Burnet KL et al (2007) Does active surveillance for men with localized prostate cancer carry psychological morbidity? Br J Urol Int 100(3):540\u2013543","journal-title":"Br J Urol Int"},{"issue":"4","key":"25_CR78","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.eururo.2014.10.028","volume":"67","author":"L Bellardita","year":"2015","unstructured":"Bellardita L et al (2015) How does active surveillance for prostate cancer affect quality of life? A systematic review. Eur Urol 67(4):637\u2013645","journal-title":"Eur Urol"}],"container-title":["Der Urologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-015-0025-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00120-015-0025-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-015-0025-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T22:51:00Z","timestamp":1654210260000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00120-015-0025-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":78,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["25"],"URL":"https:\/\/doi.org\/10.1007\/s00120-015-0025-x","relation":{},"ISSN":["0340-2592","1433-0563"],"issn-type":[{"value":"0340-2592","type":"print"},{"value":"1433-0563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2]]}}}